Anbio Biotechnology
NNNN Healthcare Medical Instruments & Supplies
Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.
Follow NNNN
Anbio Biotechnology (NNNN) Piotroski F-score
Anbio Biotechnology's Piotroski F-score for fiscal 2025 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 5 | 0.00 |
| FY2024 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 26.05% | 13.66% | Pass | 1 |
| Positive operating cash flow | (6.74m) | 2.08m | Fail | 0 |
| Rising return on assets | 26.05% | 13.66% | Pass | 1 |
| Cash flow above net income | (13.14m) | (292.40k) | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 344.45 | 10.71 | Pass | 1 |
| No new shares issued | 43,672,000 | 42,291,000 | Fail | 0 |
| Rising gross margin | 87.24% | 71.90% | Pass | 1 |
| Rising asset turnover | 0.35 | 0.47 | Fail | 0 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| EMBC Embecta Corp. compare | 7 |
| UTMD Utah Medical Products, Inc. compare | 6 |
| ANGO AngioDynamics, Inc. compare | 5 |
| NNNN Anbio Biotechnology | 5 |
| ZJYL Jin Medical International Ltd. compare | 4 |
| SMTI Sanara MedTech Inc. compare | 4 |
| OSUR OraSure Technologies, Inc. compare | 3 |
| AVR Anteris Technologies Global Corp. compare | 2 |
| STAA STAAR Surgical Company compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover